John M. Dye
A5016333842- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Hepatitis B Virus Studies
- Mosquito-borne diseases and control
- COVID-19 epidemiological studies
- Disaster Response and Management
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Virus-based gene therapy research
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- vaccines and immunoinformatics approaches
- Virology and Viral Diseases
- Monoclonal and Polyclonal Antibodies Research
- Fixed Point Theorems Analysis
- Plant Virus Research Studies
- Vector-Borne Animal Diseases
- Optimization and Variational Analysis
- Computational Drug Discovery Methods
- Vaccine Coverage and Hesitancy
- Influenza Virus Research Studies
- Bacteriophages and microbial interactions
- interferon and immune responses
United States Army Medical Research Institute of Infectious Diseases
2016-2025
United States Army
2022
The Geneva Foundation
2021
Uganda Virus Research Institute
2018
United States Department of the Army
2011-2015
Harvard University
2014
The Netherlands Cancer Institute
2014
Frederick Community College
2011
United States Army Medical Research and Development Command
2011
Medical University of South Carolina
2010
Seeking broad protection As scientists develop therapeutic antibodies and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the risk of emergent coronaviruses makes it important to also identify broadly protective antibodies. Wec et al. isolated characterized hundreds viral spike protein SARS-CoV-2 from memory B cells a survivor 2003 outbreak caused by related coronavirus, SARS-CoV. In both these viruses, facilitated entry binding angiotensin-converting enzyme...
A decoy receptor for SARS-CoV-2 For severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter human cells, the spike protein on surface of virus must bind host protein, angiotensin-converting enzyme (ACE2). soluble version is being explored as a therapeutic. Chan et al. used deep mutagenesis identify ACE2 mutants that more tightly and combined mutations further increase binding affinity (see Perspective by DeKosky). promising variant was engineered be stable dimer has protein; it...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants concern (VOCs) have negatively affected therapeutic use some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), highly potent spike glycoprotein receptor binding domain (RBD)-specific antibody. potently neutralizes...
Targeting sarbecoviruses As we continue to battle the COVID-19 pandemic, must confront possibility of new pathogenic coronaviruses emerging in humans future. With this mind, Rappazzo et al. isolated antibodies from a survivor 2003 severe acute respiratory syndrome coronavirus (SARS-CoV), used yeast display libraries introduce diversity into these antibodies, and then screened for binding SARS-CoV-2. One affinity-matured progeny strongly neutralized SARS-CoV-2, SARS-CoV, two SARS-related...
How Lassa virus breaks and enters virus, which spreads from rodents to humans, infecting about half a million people every year, can lead deadly hemorrhagic fever. Like many viruses, binds cell surface receptors. Jae et al. now show that enter cell, the requires second receptor, this one inside infected cell. This requirement sheds light on “enigmatic resistance” of bird cells observed three decades ago. Although have intracellular receptor cannot bind stopping it in its tracks. Science ,...
The molecular composition and binding epitopes of the immunoglobulin G (IgG) antibodies that circulate in blood plasma after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are unknown. Proteomic deconvolution IgG repertoire to spike glycoprotein convalescent subjects revealed response is directed predominantly (>80%) against residing outside receptor domain (RBD). In one subject, just four lineages accounted for 93.5% response, including an amino (N)-terminal...
Antibody therapies to prevent or limit filovirus infections have received modest interest in recent years, part because of early negative experimental evidence. We overcome the limitations this approach, leveraging use antibody from nonhuman primates (NHPs) that survived challenge filoviruses under controlled conditions. By using concentrated, polyclonal IgG these survivors, we treated filovirus-infected NHPs with multiple doses administered over clinical phase disease. In first study,...
Global health is threatened by emerging viral infections, which largely lack effective vaccines or therapies. Targeting host pathways that are exploited multiple viruses could offer broad-spectrum solutions. We previously reported AAK1 and GAK, kinase regulators of the adaptor proteins AP1 AP2, essential for hepatitis C virus (HCV) infection, but underlying mechanism relevance to other in vivo infections remained unknown. Here, we have discovered AP2 cotraffic with HCV particles live cells....
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We studied relationship among anti-spike ectodomain (anti-ECD), anti–receptor-binding domain (anti-RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by in vitro using convalescent plasma samples from 68 patients with COVID-19. report a strong positive correlation between both anti-RBD anti-ECD...
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options individuals remaining at risk disease 2019 (COVID-19). Monoclonal antibodies (mAbs) against viral spike protein have potential to both prevent treat COVID-19 reduce death. Here, we describe AZD7442, combination two mAbs, AZD8895 (tixagevimab) AZD1061 (cilgavimab), that simultaneously bind distinct, nonoverlapping epitopes on receptor...
Ebola virus disease causes widespread and highly fatal epidemics in human populations. Today, there is still great need for point-of-care tests diagnosis, patient management surveillance, both during post outbreaks. We present a test comprising an immunochromatographic strip smartphone reader, which detects semiquantifies Ebola-specific antibodies survivors. developed Sudan glycoprotein monoplex platform validated it using sera from 90 survivors 31 local noninfected controls. The performance...
Biological factors that influence the host range and spillover of Ebola virus (EBOV) other filoviruses remain enigmatic. While infect diverse mammalian cell lines, we report cells from African straw-colored fruit bats (Eidolon helvum) are refractory to EBOV infection. This could be explained by a single amino acid change in filovirus receptor, NPC1, which greatly reduces affinity EBOV-NPC1 interaction. We found signatures positive selection bat NPC1 concentrated at virus-receptor interface,...